Researchers combine allele-specific #Genomics with an AI-based histopathology model to identify RB1-Bi tumors and uncover synthetic lethal vulnerabilities to mitotic and DNA damage response inhibitors.
@sigtrans-sttt.bsky.social
@sigtrans-sttt.bsky.socialResearchers combine allele-specific #Genomics with an AI-based histopathology model to identify RB1-Bi tumors and uncover synthetic lethal vulnerabilities to mitotic and DNA damage response inhibitors.
@sigtrans-sttt.bsky.socialThe TRAINER phase II study evaluates #Biomarker-driven total #Neoadjuvant therapy with bevacizumab or cetuximab for high-risk #RectalCancer, reporting complete responses and high sphincter preservation.
@sigtrans-sttt.bsky.social#Fructose directly binds TOM22 and remodels the mitochondrial TOM complex, disrupting protein import, ribosome biogenesis, and #OxidativePhosphorylation, revealing a metabolism-independent mechanism of #Podocyte injury. @tsinghuauniversity.bsky.social
@sigtrans-sttt.bsky.socialA randomized phase II trial reveals that once-daily nonpeptide VCT220 reduced #bodyweight vs placebo while improving metabolic measures, with mainly mild-to-moderate #gastrointestinal adverse events supporting further evaluation. @pku1898.bsky.social
@sigtrans-sttt.bsky.socialFindings from a randomized phase III #ClinicalTrial showed that mefatinib improved progression-free survival vs gefitinib, with a pronounced benefit in #EGFR L858R-mutated #NSCLC and comparable outcomes in exon 19 deletion.
@sigtrans-sttt.bsky.socialA multicenter real-world study shows temperature-sensitive liquid #TACE (T-TACE) significantly improves survival and response in advanced #HepatocellularCarcinoma by promoting immune remodelling and CD8⁺ T-cell activation.
@sigtrans-sttt.bsky.social#Hypoxia enhances EnAd oncolytic activity via HIF-2α/HIF-1β-mediated activation of an E1A promoter HRE, revealing how tumor microenvironments drive viral replication and inform #Adenovirus-based therapies for #SolidTumors. @ox.ac.uk
@sigtrans-sttt.bsky.social#MultipleOrganDysfunction syndrome involves interconnected inflammation, microcirculatory disruption, coagulation abnormalities, cell death, DNA damage, and #OxidativeStress, creating opportunities for mechanistic and therapeutic research.
@sigtrans-sttt.bsky.socialCelebrating 10 years of Signal Transduction and Targeted Therapy and a decade of research spanning molecular mechanisms, signal transduction and targeted therapeutics.
Thank you to our global research community for being part of this journey!
@sigtrans-sttt.bsky.social#TumorHeterogeneity fuels #Cancer progression and treatment resistance through clonal evolution, stem cell plasticity, and microenvironmental crosstalk, highlighting the need for dynamic monitoring and precision therapies.
@sigtrans-sttt.bsky.social#Aging and #Cancer converge through metabolism, genome maintenance, inflammation, and #Epigenetic regulation. This review examines shared mechanisms, druggable targets, and opportunities for integrated therapies.
#STTT #OpenAccess: doi.org/10.1038/s413...
@sigtrans-sttt.bsky.socialChromosomal instability can drive tumor evolution while creating exploitable dependencies. This review connects the sources and consequences of CIN with tolerance pathways, emerging diagnostics, and therapeutic vulnerabilities.
@sigtrans-sttt.bsky.socialCell-cycle dysregulation may provide a therapeutic vulnerability in uterine #Leiomyosarcoma.
This study links CDK/cyclin–phospho-Rb signaling to uLMS and shows antitumor effects of CDK4/6 inhibition with abemaciclib.
#STTT #OpenAccess: doi.org/10.1038/s413...
#CancerBiology #MolecularOncology
@sigtrans-sttt.bsky.social#HSP90 promotes ROC1 stability in #LungAdenocarcinoma by shielding it from CHIP-mediated #Ubiquitination and degradation. HSP90 inhibition restores ROC1 destabilization and suppresses #tumor growth, defining an HSP90–CHIP–ROC1 axis.
@sigtrans-sttt.bsky.socialPARP inhibitor resistance reflects a balance between #Apoptosis and persistent #Senescence in #OvarianCancer. This study identifies BCLXL blockade as a strategy to restore apoptotic vulnerability and enhance PARPi response.
@sigtrans-sttt.bsky.socialA #chemotherapy-free strategy may reshape treatment of unresectable EGFR-mutated stage III NSCLC. The ADVANCE trial evaluates aumolertinib with #radiotherapy, showing prolonged progression-free survival with real-world support.#CancerTreatment
@sigtrans-sttt.bsky.social#Exosome heterogeneity may shape chronic lung allograft dysfunction.
An integrated single-vesicle #Multiomic atlas identifies distinct graft exosome populations and links an Ilk-high subset to pleural thickening in chronic rejection.
@sigtrans-sttt.bsky.socialProtein #Lactylation connects cellular metabolism with #Epigenetic regulation.
This review examines its molecular machinery and functions across physiology and disease, highlighting #Biomarker and therapeutic potential.
@sigtrans-sttt.bsky.social#TumorHeterogeneity and #Immunosuppressive microenvironments hinder the treatment of #SolidTumors.
This review explores diverse immune and stem-cell platforms, alongside allogeneic and in vivo engineering strategies for broader cancer treatment.
@sigtrans-sttt.bsky.socialResearchers evaluate the novel PARP inhibitor prodrug TSL-1502 in a phase 2 trial, demonstrating promising antitumor activity in BRCA-mutated HER2-negative advanced breast cancer. #ClinicalTrial
#STTT #OpenAccess: doi.org/10.1038/s413...
#CellTherapy #CancerImmunotherapy
